Warfarin & Pregnancy

Why This Topic Matters

If you are a woman of childbearing age taking warfarin, pregnancy planning is one of the most important conversations you can have with your healthcare team. Warfarin poses serious risks to a developing baby, but with careful planning and the right medical guidance, many women on long-term anticoagulation can have healthy pregnancies and healthy children.

The key word is planning. An unplanned pregnancy on warfarin is a medical emergency that requires immediate specialist involvement. A planned pregnancy with a coordinated care team is a very different — and much safer — situation.

Why Warfarin Is Dangerous in Pregnancy

Warfarin is a small molecule that easily crosses the placenta into the baby's bloodstream. While this makes it effective at preventing maternal blood clots, it also exposes the developing fetus to the same anticoagulant effects — with devastating consequences.

First Trimester (Weeks 6 to 12): Warfarin Embryopathy

Exposure to warfarin during weeks 6 through 12 of pregnancy can cause a specific pattern of birth defects called warfarin embryopathy. This affects approximately 5% to 10% of pregnancies exposed during this critical window. Features include:

• Nasal hypoplasia (underdeveloped nose bridge)
• Stippled epiphyses (abnormal bone and cartilage development)
• Limb abnormalities
• Short fingers
• Low birth weight

These defects occur because warfarin blocks vitamin K, which the developing baby needs for proper bone and cartilage formation. The vitamin K-dependent protein osteocalcin and matrix Gla protein are essential during embryonic skeletal development.

Second and Third Trimesters

After the first trimester, the risk of embryopathy decreases, but other serious risks remain:

• Central nervous system abnormalities: Including intellectual disability, optic atrophy, microcephaly, and brain hemorrhage in the fetus. These can occur with warfarin exposure at any point during pregnancy.
• Fetal bleeding: Because warfarin thins the baby's blood just as it thins yours, the fetus is at risk for spontaneous bleeding, including intracranial hemorrhage.
• Miscarriage and stillbirth: Studies show higher rates of pregnancy loss in women taking warfarin compared to alternative anticoagulants.

Planning a Pregnancy on Anticoagulation

If you are thinking about becoming pregnant and you take warfarin, the first step is to talk to your doctor — ideally a team that includes your cardiologist, hematologist, and a maternal-fetal medicine specialist (high-risk obstetrician). Here is the general approach:

1. Start the conversation early. Ideally, begin planning at least 3 to 6 months before you want to conceive. Your medical team needs time to assess your risks, choose the safest anticoagulation strategy, and set up monitoring.
2. Understand your specific risk. The safest approach depends on why you take warfarin. Women with mechanical heart valves face the highest-risk situation because they need strong, continuous anticoagulation. Women taking warfarin for a previous DVT or PE may have more flexible options.
3. Switch anticoagulants before conception. In most cases, your doctor will switch you from warfarin to an alternative anticoagulant (usually heparin-based) before you try to conceive. This eliminates fetal exposure during the critical early weeks.
4. Use reliable contraception until your anticoagulation switch is complete and your medical team confirms it is safe to conceive.
5. Get folic acid supplementation. All women planning pregnancy should take folic acid (at least 400 mcg daily), but this is especially important for women transitioning off warfarin.

Alternative Anticoagulants During Pregnancy

The main alternatives to warfarin during pregnancy are heparin-based medications. Unlike warfarin, heparin does not cross the placenta, so the baby is not exposed.

Low Molecular Weight Heparin (LMWH)

Enoxaparin (Lovenox) is the most commonly used LMWH during pregnancy. It is given as a subcutaneous injection (into the fatty tissue under your skin), usually twice daily. Benefits include:

• Does not cross the placenta
• Predictable dose-response (less monitoring needed than unfractionated heparin)
• Can be self-administered at home
• Well-studied safety profile in pregnancy

The main drawback is the need for daily injections throughout pregnancy, which can be uncomfortable and inconvenient. Some women develop bruising at injection sites or mild local reactions.

Unfractionated Heparin (UFH)

Intravenous or subcutaneous unfractionated heparin is another option, especially in the first trimester and around delivery. It has a shorter half-life than LMWH, which makes it easier to manage around labor and delivery, but it requires more frequent blood monitoring (aPTT levels).

The Mechanical Valve Dilemma

Women with mechanical heart valves face the most difficult situation. Mechanical valves require aggressive anticoagulation, and heparin-based regimens — while safer for the baby — may provide less reliable protection against valve thrombosis than warfarin. The risk of valve clotting on heparin alone is approximately 7% to 10% in some studies, compared to less than 4% on warfarin.

For mechanical valve patients, the anticoagulation strategy during pregnancy is highly individualized. Some approaches include:

• LMWH throughout pregnancy (with very close monitoring)
• LMWH in the first trimester, then warfarin in the second and early third trimester, then back to heparin near delivery
• Adjusted-dose UFH in the first trimester, warfarin in the second trimester, then UFH again near delivery

Each approach carries trade-offs between maternal valve safety and fetal exposure risk. There is no perfect option — only carefully considered ones made with your medical team.

Warfarin and Breastfeeding

Here is welcome news: warfarin is considered safe during breastfeeding. Multiple studies have shown that warfarin does not pass into breast milk in clinically significant amounts. The American Academy of Pediatrics and the American College of Chest Physicians both consider warfarin compatible with breastfeeding.

This means that after delivery, you can typically switch back to warfarin from heparin and breastfeed your baby safely. Your anticoagulation clinic will monitor your INR more closely during this transition period, as your body is also recovering from pregnancy and delivery.

What If You Discover You Are Pregnant on Warfarin?

If you find out you are pregnant and you are currently taking warfarin, contact your doctor immediately. Do not stop warfarin on your own — you still need anticoagulation, and stopping abruptly without a plan can be dangerous for you. Your doctor will likely:

1. Switch you to LMWH as quickly as possible
2. Order an ultrasound to assess the pregnancy
3. Refer you to a maternal-fetal medicine specialist if you are not already seeing one
4. Discuss the risks based on how many weeks you were exposed to warfarin

Early exposure (before 6 weeks of pregnancy) carries a lower risk of embryopathy than exposure during weeks 6 through 12. But every situation is different, and you need personalized guidance from specialists who manage high-risk pregnancies.

A Note for Partners and Families

Pregnancy on anticoagulation is stressful — not just for the patient, but for everyone around her. The daily injections, the frequent blood tests, the worry about the baby and the mother — it is a lot.

If your partner or family member is going through this, your support matters enormously. Help with injection reminders. Go to appointments together when you can. Be patient with the anxiety that comes with high-risk pregnancy. And know that with proper medical management, many women on anticoagulation have healthy pregnancies and healthy babies.

Sources

1. Regitz-Zagrosek V, et al. “2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.” European Heart Journal, 2018;39(34):3165–3241. doi:10.1093/eurheartj/ehy340
2. Chan WS, et al. “Anticoagulation of pregnant women with mechanical heart valves.” Archives of Internal Medicine, 2000;160(2):191–196. doi:10.1001/archinte.160.2.191
3. Bates SM, et al. “VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis.” Chest, 2012;141(2 Suppl):e691S–e736S. doi:10.1378/chest.11-2300
4. American Academy of Pediatrics Committee on Drugs. “Transfer of drugs and therapeutics into human breast milk.” Pediatrics, 2013;132(3):e756–e789. doi:10.1542/peds.2013-1985
5. Otto CM, et al. “2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease.” Circulation, 2021;143(5):e72–e227. doi:10.1161/CIR.0000000000000923